ATE245442T1 - Getrocknete zubereitung von bluttfaktoren, enthaltend trehalose - Google Patents

Getrocknete zubereitung von bluttfaktoren, enthaltend trehalose

Info

Publication number
ATE245442T1
ATE245442T1 AT96900633T AT96900633T ATE245442T1 AT E245442 T1 ATE245442 T1 AT E245442T1 AT 96900633 T AT96900633 T AT 96900633T AT 96900633 T AT96900633 T AT 96900633T AT E245442 T1 ATE245442 T1 AT E245442T1
Authority
AT
Austria
Prior art keywords
dried preparation
containing trehalose
blood factors
factors containing
trehalose
Prior art date
Application number
AT96900633T
Other languages
English (en)
Inventor
Bruce Joseph Roser
Original Assignee
Elan Drug Delivery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Drug Delivery Ltd filed Critical Elan Drug Delivery Ltd
Application granted granted Critical
Publication of ATE245442T1 publication Critical patent/ATE245442T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4846Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT96900633T 1995-01-19 1996-01-19 Getrocknete zubereitung von bluttfaktoren, enthaltend trehalose ATE245442T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9501040.1A GB9501040D0 (en) 1995-01-19 1995-01-19 Dried composition
PCT/GB1996/000119 WO1996022107A1 (en) 1995-01-19 1996-01-19 Dried blood factor composition comprising trehalose

Publications (1)

Publication Number Publication Date
ATE245442T1 true ATE245442T1 (de) 2003-08-15

Family

ID=10768253

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03002147T ATE413885T1 (de) 1995-01-19 1996-01-19 Getrocknete blutfaktorzusammensetzung mit trehalose
AT96900633T ATE245442T1 (de) 1995-01-19 1996-01-19 Getrocknete zubereitung von bluttfaktoren, enthaltend trehalose

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT03002147T ATE413885T1 (de) 1995-01-19 1996-01-19 Getrocknete blutfaktorzusammensetzung mit trehalose

Country Status (15)

Country Link
US (2) US6649386B2 (de)
EP (4) EP2258402A3 (de)
JP (1) JP3898221B2 (de)
KR (1) KR100417593B1 (de)
CN (1) CN1152713C (de)
AT (2) ATE413885T1 (de)
AU (1) AU704317B2 (de)
CA (2) CA2671383C (de)
DE (2) DE69637749D1 (de)
DK (2) DK0871476T3 (de)
ES (2) ES2316658T3 (de)
GB (1) GB9501040D0 (de)
PT (2) PT1308170E (de)
SI (1) SI1308170T1 (de)
WO (1) WO1996022107A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244824B2 (en) * 1995-01-19 2007-07-17 Quadrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US7253262B2 (en) * 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
GB9501040D0 (en) * 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US6964771B1 (en) 1995-06-07 2005-11-15 Elan Drug Delivery Limited Method for stably incorporating substances within dry, foamed glass matrices
US6632648B1 (en) * 1996-05-14 2003-10-14 Elan Drug Delivery Limited Methods of terminal sterilization of fibrinogen
GB9616536D0 (en) * 1996-08-06 1996-09-25 Quadrant Holdings Cambridge Co-amoxiclav dosage form
AUPO871997A0 (en) * 1997-08-25 1997-09-18 Csl Limited Dried biologically or therapeutically active preparations
DK1820516T3 (da) 1999-02-22 2013-10-28 Univ Connecticut Nye albuminfrie faktor VIII-præparater
BR0211842A (pt) * 2001-08-10 2004-08-31 Hayashibara Biochem Lab Associado, processos para produzir um associado de trealose ou maltitol e um ou mais compostos de ìon metálico, um produto em pó e um alimento marinho seco, método para formar um associado de trealose ou maltitol e um ou mais compostos de ìon metálico, composição, produto em pó, agente e tempero para alimentos
CA2538794C (en) 2003-09-12 2016-04-19 Antigenics, Inc. Vaccine for treatment and prevention of herpes simplex virus infection
EP1755652B1 (de) * 2004-03-19 2010-11-24 Baxter International Inc. Faktor ixa zur behandlung von blutungsstörungen
DE602005016402D1 (de) 2004-05-24 2009-10-15 Genvault Corp Stabile lagerung von protein und stabile lagerung von nukleinsäure in wiedergewinnbarer form
KR100624013B1 (ko) 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
US8133484B2 (en) 2006-12-15 2012-03-13 Lifebond Ltd Hemostatic materials and dressing
JP2010513462A (ja) * 2006-12-20 2010-04-30 バイエル・ヘルスケア・エルエルシー 第VIIおよび第VIIa因子組成物
EP1958618A1 (de) 2007-02-15 2008-08-20 Octapharma AG Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren
BRPI0821591A2 (pt) * 2007-12-21 2016-05-03 Inspiration Biopharmaceuticals Inc composição liofilizada e métodos de preparação de composição seca estável do fator ix e de liofilização de formulação farmacêutica
SG187410A1 (en) 2007-12-28 2013-02-28 Baxter Int Recombinant vwf formulations
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
WO2010031007A2 (en) 2008-09-12 2010-03-18 Genvault Corporation Matrices and media for storage and stabilization of biomolecules
EP2349314B1 (de) 2008-10-21 2013-02-27 Baxter International Inc. Lyophilisierte rekombinante vwf-formulierungen
MX339060B (es) 2008-11-07 2016-05-09 Baxter Int Formulaciones del factor viii.
WO2011077388A1 (en) 2009-12-22 2011-06-30 Lifebond Ltd Modification of enzymatic crosslinkers for controlling properties of crosslinked matrices
EP2732262A4 (de) * 2011-07-13 2014-12-10 Denator Ab Verfahren zur stabilisierung von flüssigen biologischen proben
CN102416171B (zh) * 2011-12-06 2013-12-25 中国医学科学院输血研究所 高纯度凝血酶原复合物制品干热病毒灭活过程中的保护剂
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
AU2014368594B2 (en) * 2013-12-19 2020-03-05 Janssen Vaccines & Prevention B.V. Improved formulations for virosomes
CN106687126B (zh) 2014-08-04 2020-07-28 杰特有限公司 因子viii制剂
EA201792501A1 (ru) 2015-05-13 2018-10-31 Эйдженус Инк. Вакцины для лечения и профилактики рака
CN107333750A (zh) * 2017-06-11 2017-11-10 成都吱吖科技有限公司 一种长时血液细胞稳定剂
MA52363A (fr) 2018-04-26 2021-03-03 Agenus Inc Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation
US11998654B2 (en) 2018-07-12 2024-06-04 Bard Shannon Limited Securing implants and medical devices
WO2021001522A1 (en) 2019-07-04 2021-01-07 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
JP2025512143A (ja) 2020-11-09 2025-04-17 武田薬品工業株式会社 酸化ケイ素吸着を使用する血漿からのfviiiの精製
WO2022261716A1 (en) * 2021-06-16 2022-12-22 Exopharm Limited Aqueous formulations for preservation of extracellular vesicles
WO2024102796A2 (en) * 2022-11-08 2024-05-16 University Of Wyoming Stabilization of biologics and human blood clotting factor viii in a dry state

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361509A (en) 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4495175A (en) * 1982-08-05 1985-01-22 University Of Rochester Preparation of highly purified human antihemophilic factor
FI86885C (fi) 1984-04-20 1992-10-26 Genentech Inc Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill
EP0182448A3 (de) 1984-08-24 1987-10-28 Genetics Institute, Inc. Verfahren zur Herstellung von Faktor VIII und verwandte Produkte
JPH0779694B2 (ja) * 1985-07-09 1995-08-30 カドラント バイオリソ−シズ リミテツド 蛋白質および同類品の保護
US4758657A (en) * 1985-07-11 1988-07-19 Armour Pharmaceutical Company Method of purifying Factor VIII:C
US4806343A (en) * 1986-03-13 1989-02-21 University Of Southwestern Louisiana Cryogenic protectant for proteins
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
CA2051092C (en) * 1990-09-12 2002-07-23 Stephen A. Livesey Method and apparatus for cryopreparation, dry stabilization and rehydration of biological suspensions
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
US5288853A (en) * 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
CA2124690C (en) * 1992-10-02 2007-09-11 Thomas Osterberg Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
WO1995003332A1 (en) * 1993-07-23 1995-02-02 Baxter International Inc. Activated human factor viii and method of preparation
US5576291A (en) * 1993-09-13 1996-11-19 Baxter International Inc. Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
US5955448A (en) * 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
US7253262B2 (en) * 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
GB9501040D0 (en) * 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US5804420A (en) * 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
DK1820516T3 (da) * 1999-02-22 2013-10-28 Univ Connecticut Nye albuminfrie faktor VIII-præparater

Also Published As

Publication number Publication date
EP1308170A2 (de) 2003-05-07
US6649386B2 (en) 2003-11-18
CA2671383A1 (en) 1996-07-25
DK1308170T3 (da) 2008-12-15
WO1996022107A1 (en) 1996-07-25
DK0871476T3 (da) 2003-11-10
EP0871476B1 (de) 2003-07-23
CN1179107A (zh) 1998-04-15
ES2202425T3 (es) 2004-04-01
EP1974741A1 (de) 2008-10-01
SI1308170T1 (sl) 2009-04-30
US20020128207A1 (en) 2002-09-12
PT1308170E (pt) 2008-12-26
JP3898221B2 (ja) 2007-03-28
KR19980701500A (ko) 1998-05-15
EP1308170B1 (de) 2008-11-12
DE69629209T2 (de) 2004-02-19
ATE413885T1 (de) 2008-11-15
EP0871476A1 (de) 1998-10-21
EP2258402A3 (de) 2011-01-05
AU4454096A (en) 1996-08-07
JPH11503719A (ja) 1999-03-30
PT871476E (pt) 2003-12-31
CA2210872C (en) 2009-09-08
EP1308170A3 (de) 2004-03-03
CN1152713C (zh) 2004-06-09
ES2316658T3 (es) 2009-04-16
CA2671383C (en) 2012-04-24
GB9501040D0 (en) 1995-03-08
US7803911B2 (en) 2010-09-28
AU704317B2 (en) 1999-04-22
DE69637749D1 (de) 2008-12-24
DE69629209D1 (de) 2003-08-28
KR100417593B1 (ko) 2004-04-30
EP2258402A2 (de) 2010-12-08
CA2210872A1 (en) 1996-07-25
US20090149388A1 (en) 2009-06-11

Similar Documents

Publication Publication Date Title
ATE245442T1 (de) Getrocknete zubereitung von bluttfaktoren, enthaltend trehalose
MX9304710A (es) Composicion farmaceutica y/o cosmetica y su uso.
NO179911C (no) Optisk aktivt 5H-pyrrolo[3,4-bÅpyrazinderivat samt farmasöytiske preparater inneholdende derivatet
NO874329D0 (no) Hylser for "sommerfugl"-naaler.
DE3785684D1 (de) Pyrrolidinamid-derivate von acylaminosaeure, pharmazeutische zusammensetzung und verwendung.
ATE105297T1 (de) Derivate von 2'-halomethyliden, 2'-ethenyliden und 2'-ethynylcytidin, uridin und guanosin.
ATE82857T1 (de) Interleukin-2-zusammensetzungen.
DE3576505D1 (de) 3,4-dihydrobenzopyranverbindungen und diese enthaltende pharmazeutische zusammenstellungen.
ATE154507T1 (de) Dentalwerkstoffe auf basis von (meth)-acrylaten
DK0453603T3 (da) Piroxicamholdige farmaceutiske præparater til topisk anvendelse
DK0437225T3 (da) Topiske præparater
DE69208681D1 (de) Verwendungen von 1,1,1,3,3,3-hexafluoropropan
FI923751A0 (fi) Hexahydrobenso/f/kinolinoner.
ATE26109T1 (de) Acetylcystein-salze, ihre herstellung und verwendung.
FI883255L (fi) Maenniskans papillomavirus, typ 41 dess dna och av dna:et kodade protein.
ATE132877T1 (de) Emulgatorfreie emulsionspolymere in pharmazeutischen zubereitungen mit verzögerter wirkstofffreigabe und ihre herstellung
DE3889336D1 (de) Alkyltetramethylcyclohexan-derivate und deren verwendung als duftstoffe.
DE68912432D1 (de) Pharmazeutische Zusammensetzung, verwendbar bei der Behandlung von Herzgefässerkrankungen.
KR900700471A (ko) 신규의 2,3-티오모르폴린디온-2-옥심유도체, 이들을 함유하는 약제학적 조성물 및 제법
IT1237087B (it) N,n'-di-(trimetossibenzoil) piperazine 2-metossicarbonil sostituite, procedimento per preparare le stesse e composti terapeutici che le contengono.
DE3869232D1 (de) Abkoemmlinge von bornan-3-spiro-l'-cyclopentan und diese enthaltende riechstoffzusammensetzungen.
MX9203261A (es) Nuevas 12-amino-piridazino [4',5':3,4] pirrolo[2,1-a]-isoquinolinas y composiciones farmaceuticas que las contienen.
DE68916472D1 (de) Polyäthylen-Zusammensetzung.
ATE82138T1 (de) Geregelte verabreichungszusammensetzung.
IT1207432B (it) Dispositivi per la chiusura rapida di calzature per attivita'sciatorie, coordinati per la tenuta differenziabile e l'articolazione controllata degli arti calzati.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0871476

Country of ref document: EP

EEFA Change of the company name